New Alzheimer’s study explores cord blood cells

New Alzheimer’s study explores cord blood cells

Researchers in China have launched a new clinical study investigating the use of cells from umbilical cord blood in people with Alzheimer’s disease.

The Phase 1 study which began in July 2025 involves 30 participants. All will continue their usual Alzheimer’s medications and will be randomly assigned to receive either cord blood cells or a placebo, delivered intravenously.

It will assess whether the treatment reduces inflammation in the body, which is thought to play a role in Alzheimer’s disease.

This is an early-stage (Phase I) trial designed to determine whether the approach is suitable for further research. The study is expected to conclude in 2026, and no results have been reported yet.

See the clinical trial here.